LAB

Standard BioTools Inc. (LAB) - Q2 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2025. Standard BioTools Inc. is a life science tools company providing instrumentation, consumables, and services for proteomics and genomics. A material strategic shift occurred during the quarter: on June 22, 2025, the Company entered into a Stock Purchase Agreement to sell its SomaScan Business (SomaLogic and Sengenics) to Illumina, Inc. Consequently, the SomaScan Business is classified as discontinued operations and held-for-sale assets/liabilities are segregated on the balance sheet. The Company now reports as a single operating segment focused on mass cytometry and microfluidics.

Key Financial Metrics (Continuing Operations)

Material Changes vs. Prior Period

• Revenue Decline: Total revenue for continuing operations decreased 3% in Q2 and 5% YTD compared to 2024. Instrument revenue dropped 26% in Q2 due to lower unit sales of the CyTOF XT, partially offset by an 18% increase in consumables revenue.
• Discontinued Operations: The SomaScan Business generated $20.2 million in revenue for Q2 2025 but resulted in a net loss of $15.8 million, primarily due to $10.5 million in transaction expenses related to the sale to Illumina.
• Expense Reduction: Operating expenses for continuing operations decreased 11% in Q2 and 23% YTD. This was driven by a 90% reduction in transaction/integration expenses (following the 2024 SomaLogic merger) and a 70% reduction in restructuring charges.
• SG&A Increase: Selling, General, and Administrative expenses increased 13% YTD. Management attributes this to "stranded costs" where shared corporate overhead previously allocated to the SomaScan Business now remains with continuing operations.
• Other Income: Other income increased significantly due to foreign currency transaction gains ($5.5 million YTD) and a $3.4 million gain from the decrease in fair value of contingent consideration liability.

Guidance, Outlook, and Risks

• Transaction with Illumina: The Company expects to sell the SomaScan Business for up to $425 million ($350 million upfront + up to $75 million earnout). Closing is expected in the first half of 2026, subject to regulatory approval (Hart-Scott-Rodino Act).
• Liquidity: The Company holds $237.1 million in cash, cash equivalents, and short-term investments. Management believes this is sufficient to fund operations for at least the next 12 months.
• Strategic Focus: Post-transaction, the Company will focus on mass cytometry and microfluidics. Management plans to continue cost optimization and R&D investments in single-cell and spatial proteomics.
• Risks: Key risks include the failure to consummate the Illumina transaction, potential disruption to business operations during the divestiture, and the inability to realize anticipated cost savings. The Company also faces ongoing litigation regarding the prior SomaLogic merger and a dispute with a shareholder representative regarding milestone payments.

Investor Verification Checklist

• Transaction Closing Conditions: Verify the status of the Hart-Scott-Rodino waiting period and any regulatory hurdles for the Illumina sale.
• Stranded Costs: Assess the sustainability of SG&A expenses now that the SomaScan Business is excluded; determine if further cost-cutting is required to achieve profitability in the remaining business.
• Instrument Sales Pipeline: Investigate the cause of the 26% drop in instrument revenue and the outlook for CyTOF XT placements.
• Legal Exposure: Review the status of the Delaware Court of Chancery litigation regarding the SomaLogic merger and the Palamedrix milestone dispute.
• Deferred Revenue: Note that $42.9 million in deferred revenue remains, with $7.4 million expected to be recognized in the remainder of 2025.